glp-1 in development What is the pipeline for future medications for obesity? Market Overview: GLP-1 Agonists and

GIP is released from the upper small intestine in response to nutrients

With NEX, pharma companies, metabolic health clinics, and prescribing networks can launch branded GLP-1 companion apps in months and integrate multiple biosensors with ease, while generating real-world evidence to strengthen reimbursement strategies and scale patient engagement globally

Non-responders after gastric bypass surgery for morbid obesity: peptide hormones and glucose homeostasis

Over time, the body develops some tolerance to the gastric slowing effect, so their gastric emptying delay is less acute (and thus they have milder postprandial effect relative to short-acting ones) ( [112] ) ( [113] )

Predictors for repeated hyperkalemia and potassium trajectories in high risk patientsa population-based cohort study

However, data is extremely limited